With cancer cases on the rise globally, particularly in organs prone to metastatic spread like the lungs, breast, and colon, liver metastases have become increasingly prevalent.
For instance, according to the WHO, colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases. Similarly, as per the World Cancer Research Fund International, there were more than 1.9 million new cases of colorectal cancer in 2020.
Further, the Memorial Sloan Kettering Cancer Center stats that up to 70 percent of people with colorectal cancer eventually develop liver metastases.
Thus, with increasing number of cancer diagnosis coupled with high potential of liver metastasis, the demand for effective treatment options has soared, thereby propelling the market growth.
Moreover, collaborative efforts between healthcare providers and regulatory authorities are aimed at streamlining treatment protocols and ensuring broader accessibility to novel therapies, thus fueling the market growth.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Liver metastases treatment market size was valued at USD 1.6 billion in 2023 and is anticipated to grow at 6.7% CAGR during 2024-2032, driven by the rising incidence of cancers, such as colorectal, breast, and lung cancer.
The hospital pharmacies segment in the market is likely to record 6.4% CAGR between 2024-2032, as they offer a comprehensive range of specialized medications and therapies that are crucial for the effective management of liver metastases.
North America liver metastases treatment market size was valued at USD 680.3 million in 2023 and is anticipated to reach USD 1.2 billion by 2032, attributed to robust healthcare policies and insurance coverage.
AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Ono Pharmaceutical, and Pfizer, Inc.